Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Parvus

- PMLiVE

Roche picks up European rights to diabetes implant

Will distribute Senseonics' Eversense CGM System in Germany, Italy and the Netherlands

Roche's Perjeta pertuzumab

NICE rejects Roche’s breast cancer drug Perjeta

Says the treatment's long-term benefits are unclear

Roche Basel Switzerland

Roche gets first approval for PD-L1 inhibitor Tecentriq

Expects to launch bladder cancer treatment within the next two weeks

Deal Watch March 2016

AstraZeneca, Roche, Sanofi and Valeant are featured in this month’s roundup of pharma deals

Roche - Basel

Cancer drugs help Roche beat expectations in first quarter

Sales of Avastin and Herceptin show no sign of slowing down

- PMLiVE

AbbVie and Roche to launch Venclexta within a week

FDA approves first-in-class BCL-2 inhibitor to treat chronic lymphocytic leukaemia patients

- PMLiVE

IQWiG unimpressed with Cosentyx in two new indications

Concludes Novartis drug has no added benefit in ankylosing spondylitis or psoriatic arthritis

- PMLiVE

Roche integrates diabetes app with Apple Health

Accu-Chek Connect will allow patients to share data with the iPhone system

Roche - Basel

Roche boosts cancer portfolio with $1bn Blueprint deal

Collaboration will focus on the development of its ‘immunokinases’ immuno-oncology treatment

AZ and Roche fund PatientsLikeMe cancer patient outcomes study

The online patient network's cancer experience research will also involve M2Gen

Roche Basel Switzerland

Roche chalks up second approval for Gazyva

FDA approves additional indication as a treatment for follicular lymphoma

- PMLiVE

Roche and AZ claim FDA breakthrough status for new drugs

Designation could speed up development for Roche’s ocrelizumab and AZ’s durvalumab 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links